Most cases of acute leukemia can be assigned to the myeloid, B or T lineage. In a few cases, definitive assignment cannot be achieved because blasts express antigens of more than one lineage. A subset of these, referred to as acute bilineal leukemias (aBLLs), is characterized by the presence of more than one population of blasts, each comprising a single lineage. We identified 19 cases of aBLL, including 10 mixed T and myeloid (T-My) and nine mixed B and myeloid (B-My); no mixed B and T cases were identified. Cytogenetic data were available for 16 patients. Three of seven patients with B-My had a t(9;22)(q34q11.2), two had 11q23 translocations and one had del(9). Two of nine patients with T-My had 2p13 translocations; five had other unrelated abnormalities. Of 16 patients with outcome data, only six achieved complete remission and only two remain free of disease 2.5 and 4.5 years after chemotherapy or stem cell transplantation. aBLL is a rare disease that combines B or T and myeloid blasts. Cytogenetic abnormalities of t(9;22) and 11q23 are common in, and may be restricted to, B-My cases, while T-My cases have frequent but generally nonrecurring abnormalities. Both types of aBLL are associated with poor outcome.
Introduction
The great majority of acute leukemias can be unequivocally assigned to the myeloid, B-or T-lymphoid lineage. [1] [2] [3] [4] However, with the immunophenotypic markers typically used to characterize acute leukemia, a small but heterogeneous subset of leukemias cannot be clearly identified. Such tumors have been referred to as acute leukemias of ambiguous lineage in the World Health Organization classification. 4 While many cases of ambiguous lineage leukemia are characterized by a 'stem-cell' phenotype and lack evidence of differentiation (i.e. acute undifferentiated leukemia), others demonstrate a multiplicity of antigens that are associated with two or more different lineages. Most of these differentiated cases comprise a single dominant population of blasts characterized by the expression of both myeloid-and lymphoid-associated antigens. The absence of a lineage-specific phenotype in these cases precludes definitive lineage assignment. Other cases, however, are characterized by more than one population of blasts, each of which exhibits an unequivocal, lineage-specific pattern of differentiation. [5] [6] [7] [8] Nomenclature for such cases has been confusing; in older literature, these have variably been referred to as hybrid acute leukemia or mixed lineage leukemia. More recently, the European Group for Immunologic classification of Leukemia (EGIL) has proposed standard criteria for the diagnosis of biphenotypic acute leukemia (BAL), but these criteria were mainly designed to recognize cases of antigen coexpression, and did not explicitly address cases with dual leukemic populations and distinguish them from those with shared antigens. 3 In this study, we investigated a series of cases of leukemias with distinct populations of blasts; we will employ the term acute bilineal leukemia (aBLL) to describe them.
The distinction between true aBLL and biphenotypic leukemia is not well established in the literature. In most reports, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] cases of aBLL are combined with BAL. While some reports describe morphologically distinct blast populations in some of the cases of BAL, dimorphic populations do not necessarily prove that the two blast populations are phenotypically different, and few specifically report cases in which immunophenotypic distinction between blast populations are readily made. 11, 19 Despite gaining increasing recognition due to sophisticated methods of modern immunophenotypic analysis, the lack of widely accepted criteria for recognizing and defining aBLL has prevented a clear understanding of its biology and the establishment of standard therapeutic protocols.
Methods

Case selection
Owing to its high sensitivity in characterizing lineage-associated patterns of hematolymphoid maturation, multiparameter flow cytometry was the diagnostic method by which cases were selected for analysis. Archived files of The Johns Hopkins Hospital Clinical Flow Cytometry Lab containing 1477 cases of acute leukemia seen over a 10-year period were searched for cases of acute leukemia that were characterized by distinct myeloid and lymphoid blast populations. Each blast population expressed a combination of antigens that, by accepted convention, demonstrated lineage specificity. Blasts were generally gated on displays of CD45 vs right-angle scatter, and antigen expression was considered positive if a distinct sub-population of blasts accounting for at least 10% of the cells expressed the marker, or, in the case of homogeneously expressed antigens, the intensity of expression was greater than that of isotypic or other appropriate controls by a minimum of 50 channels on a log scale. Furthermore, in all cases in this series, the light scatter properties of the two populations of blasts were sufficiently different to allow the recognition of dual populations; although there was overlap between populations in many cases, display of light scatter vs antigens could, in all cases, identify distinct populations ( Figure 1 ). Cases characterized only by a single blast population that expressed both myeloid and lymphoid markers on the same cells, resulting in what would be more typically defined as biphenotypic leukemia, were not included in this series.
Immunophenotypic profiles were correlated with clinical parameters, cytogenetic analysis and morphologic examination, if available. Clinical parameters included patient age, race, peripheral white cell count at diagnosis and history of hematologic malignancy. Cytogenetic studies comprised standard G-banding karyotypic analysis, and morphology examination was performed on Giemsa-stained marrow aspirate and peripheral blood smears. The clinicopathologic characteristics of these cases were then compared to survival data. Studies were approved by the Johns Hopkins University institutional review board.
Flow cytometry immunophenotyping
Flow cytometry immunophenotyping was performed on fresh bone marrow or blood specimens. Single-cell suspensions were incubated with combinations of monoclonal antibodies in threeor four-color immunofluorescence (Becton Dickinson, San Jose, CA, USA) using concentrations titrated for optimal staining. Antibodies used in the analysis recognized stem cell and panleukocyte antigens including CD45, CD34, CD38, TdT and HLA-DR; myeloid-associated antigens including myeloperox- idase (MPO), CD117, CD33, CD13, CD15, CD11b, CD64 and CD14; and lymphoid-associated antigens, including surface and cytoplasmic CD3, CD5, CD7, CD2, CD4, CD8, CD1a, CD10, CD19, CD22, CD20, CD9, CD79a, CD24 and CD56. Selected antibody combinations were conjugated to fluorescein isothiocyanate, phycoerythrin, peridinin chlorophyll protein and allophycocyanin. Specimens were analyzed on a BD FACSCalibur flow cytometry system (Becton Dickinson), and calibration beads (Calibrite; BD) were routinely used for monitoring and optimizing the instrument settings. List mode data files were acquired and analyzed for each specimen using the CellQuest and Paint-A-Gate software programs, respectively (Becton Dickinson).
Results
We identified 19 cases of aBLL (Table 1 ) diagnosed in both adult and pediatric patients who ranged in age from 0.3 to 69 years (median 18). Eighteen patients presented with marrow disease; one patient who presented with primary lymph node involvement subsequently relapsed in the marrow. Seventeen cases represented de novo acute leukemia, one represented transformation of a myelodysplastic syndrome and another represented relapse in a patient originally diagnosed as T-ALL. Peripheral white blood cell count at presentation ranged from 1800 to 522 500/ml (median 38 000/ml). While all cases included a myeloid component, 10 were characterized by a T-lymphoid component and nine by a B-lymphoid component; no cases comprised a combination of B-and T-lymphoid blast populations. By flow cytometric analysis, each case displayed disparate blast populations readily identified by either the combination of forward and right-angle light scatter or forward scatter and antigen pattern. All blast populations expressed CD45 and low right-angle light scatter. CD38 was positive in both blast populations in all 17 cases tested, though other blast markers including CD34 and HLA-DR were variably expressed ( Table 2 ).
Of the 10 T-myeloid leukemias, myeloid blasts accounted for 13-87% of total leukemic cells and demonstrated unequivocal myeloid phenotypes. Notably, MPO was expressed in seven of eight cases tested, CD13 was expressed in all cases and CD33 was expressed in 9 of 10 cases tested. The single case that lacked MPO expression (case no. 1) demonstrated an immunophenotypic profile typical of minimally differentiated (M0) myeloid blasts with bright expression of CD13, CD33 and CD117 on blasts that were larger than those that expressed T-cell markers. Two cases that were not tested for MPO showed positivity for a variety of other myeloid-associated antigens that in combination supported a myeloid differentiation pattern. Even when the myeloblastic component was small, as in case 12 with only 6% myeloblasts, the aberrant coexpression of CD117, CD64 and CD7 indicated a clearly abnormal phenotype that could not represent residual myeloid elements. Three cases showed a suggestion of monocytic maturation, with expression of CD14; whereas CD64 was expressed in even more cases, in the CD14-negative cases this was at low intensity and not at a level with specificity for monocyte maturation. The T-cell components of all 10 T-myeloid leukemias demonstrated expression of both CD7 and, somewhat surprisingly, of sCD3, though the latter was only present on a small subset of the leukemic blasts in essentially all cases; it was also expressed at low density, indicating that these were not normal T cells contaminating the leukemic gate. CD2 was present in 4/10 cases and CD5 in 7/10. In addition, both CD4 and CD8 were negative on the T-cell component in all seven cases in which it was tested. Although one case demonstrated dim CD8 expression without TdT (case no. 1), the combination of CD3, CD10 and CD1a expression in that case confirmed an immature T-cell phenotype.
The myeloid components of the nine B-myeloid cases accounted for 6-88% of leukemic cells, and also demonstrated unequivocal myeloid phenotypes by flow cytometric analysis. The majority of cases studied utilized MPO to establish the myeloid phenotype. However, two cases lacked MPO positivity (case nos. 16 and 17) and one case did not have MPO tested Immunophenotypic profiles of aBLL cases by flow cytometric analysis
Mixed T-myeloid leukemias
Case % blast % M % T CD34 CD38 HLADR MPO CD117 CD33 CD13 CD15 CD11b CD14 CD64 TdT sCD3 cCD3 CD5 CD7 CD2 CD4 CD8 CD1a CD10 CD19 CD56 
Abbreviations: b, both myeloid and lymphoid components; B, B-lymphoid component only; M, myeloid component only; T, T-lymphoid component only; n, neither myeloid nor lymphoid components; ND, not done. All cases were CD45-positive on all populations (not shown).
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Leukemia (case no. 19). These three patients' blasts expressed several myeloid-associated antigens, which in combination with the distinct light scatter characteristics permitted myeloid lineage assignment. Three of the cases demonstrated monocytic maturation, with expression of CD14 and CD64. The B-lymphoid blasts in these bilineal cases demonstrated both CD19 and CD22 expression in all nine cases, and CD20 expression in six of eight cases tested. Surface membrane immunoglobulin was absent from all five cases in which it was tested, including three cases that were CD20 þ . Although CD10 was expressed by the B-lymphoid blasts in only six of nine cases, relatively bright TdT was expressed in eight cases, including those that were CD10À.
Cytogenetic data at diagnosis were available for 16 cases ( Table 1 ). Three of the seven patients with B-myeloid leukemia and available cytogenetics had a t(9;22)(q34;q11.2), two had 11q23 abnormalities and one had del(9p). Of the nine cases with T-myeloid leukemia and available cytogenetics, two had 2p13 translocations, two had complex karyotypes (case no. 5 and 8), and del(12p), add(7) and inv(1) were seen in one patient each. Normal karyotypes were found in one B-myeloid and two T-myeloid patients. With the exception of case 12, karyotyping studies showed only one abnormal clone, suggesting that in general there were no separate clones that might have corresponded to the lymphoid and myeloid leukemic components.
Giemsa-stained smears of both bone marrow and peripheral blood specimens were available for morphologic review in six cases at diagnosis; marrow aspirate smears alone were available in five additional cases and blood smears alone were available in two additional cases. Of the 13 cases available for morphologic examination, a dimorphic blast population was apparent in five T-myeloid cases and two B-myeloid cases (Figure 2) . In all seven cases, the myeloid blasts were large and had ample cytoplasm; only one case had Auer rods, and there was relatively little granulocytic maturation noted. Some cases showed morphologic features of monocytic differentiation. None of the leukemias was characterized by promyelocyte morphology. The lymphoid blasts in all cases examined were relatively small and had high nuclear-to-cytoplasmic ratios. Although the lymphoblasts in three cases demonstrated 'hand mirror' morphology, there were no cytologic features that reliably distinguished B-lymphoid blasts from T-lymphoid blasts. Cytochemical analysis was performed on three cases, two with T-lymphoid blasts. These studies showed diffuse cytoplasmic reactivity with MPO in the myeloid blasts and focal, paranuclear reactivity for acid phosphatase in the T-lymphoid blasts.
Clinical outcome data were available for nine T-myeloid cases and seven B-myeloid cases (Figure 3 ). Only six of these 16 cases achieved complete remission after induction chemotherapy. Three patients who had achieved remission underwent subsequent stem cell transplantation; while two transplant patients had B-myeloid phenotypes and ultimately relapsed and died (case nos. 11 and 19), the third had a T-myeloid phenotype and remains disease-free 2.5 years after diagnosis (case no. 5). The three remaining patients, two T-myeloid (cases nos. 4 and 6) and one B-myeloid (case no. 17), subsequently relapsed following chemotherapy and all died. Six T-myeloid and four B-myeloid patients failed induction chemotherapy. Two T-myeloid patients (case nos. 1 and 8) and one B-myeloid patient (case no. 18) died within 10 days of diagnosis. Although seven patients who failed induction were able to tolerate transplantation, six of these, two with B-myeloid and four with T-myeloid phenotypes, relapsed soon after and died (case nos. 13, 14, 9, 2, 7 and 3). One patient who had failed induction and underwent subsequent transplantation appears to have been cured, as he remains in durable remission 4.5 years after diagnosis with a Ph þ B-myeloid leukemia (case no. 12). Interestingly, this patient had the smallest percentage of myeloid blasts seen in any of our cases, though these had an aberrant myeloid phenotype, with coexpression of CD7, indicating that these could not have represented normal myeloid elements.
Discussion
Although the great majority of acute leukemias can be classified as B, T or myeloid lineage, a small percentage have features of more than one lineage such that definitive classification is not possible. Early reports of biphenotypic and bilineal leukemia recognized these two types of cases. [5] [6] [7] [8] 13, 14 The scoring system devised by EGIL attempted to standardize a definition of biphenotypic leukemia, though it did not clearly address bilineal cases. 3, 9 Several publications have appeared using the EGIL criteria to describe series of BAL. 10, 12, 16, 18 Although many of these studies have acknowledged that in some cases distinct populations of blasts can be identified either morphologically or immunophenotypically, for the most part these studies have not distinguished cases with simultaneous expression of antigens on the same cells from those with separate populations.
In this study, we collected a series of cases that satisfied criteria for aBLL in that two distinct populations of leukemic cells could be identified, each showing clear assignment to a particular lineage. Immunologic profiles were deemed lineagespecific if they demonstrated certain combinations of antigens and/or if they included highly specific single antigens, such as MPO or CD3. Myeloid components that lacked MPO expressed either a monocytic or a minimally differentiated myeloid phenotype. While cases of T/B biphenotypic leukemia or even triphenotypic leukemia have been described, 9, 12, 18 in our series, all cases had a myeloid and single lymphoid component.
The phenotypes seen in our cases were somewhat unusual in that the lymphoid and myeloid lineages were well developed, with expression of mature, lineage-specific markers such as sCD3 or CD20 in the lymphoid component in most cases, and mature monocytic markers in the myeloid component in many cases. While this may, in part, represent a selection bias--we only included cases in which two different unambiguous lineages could be identified--it also illustrates that even when a leukemia arises from a primitive multipotent progenitor it is possible for the leukemic cell to maintain much of a normal differentiation program.
It should be noted that we did not have a minimal criterion specifying a percentage of blasts of a particular subtype required to diagnose bilineal leukemia. In only 8/19 cases did we identify more than 20% blasts of both lineages, but based on the aberrant phenotypic patterns identified, even cases with small numbers of blasts represented leukemic and not reactive populations of the minor lineage. In most descriptions of BAL, the criterion used to identify antigen expression is 20% reactivity on the blast population, or sometimes, in the case of MPO or TdT, 10%. 3, 12, 18 Our results indicate that application of such a criterion might result in a significant underdiagnosis of bilineal leukemias.
Karyotypic analysis suggested that t(9;22) and 11q23 abnormalities are relatively common recurring translocations in aBLL, but appear to be restricted to those with a B-lymphoid and myeloid component. By contrast, T-myeloid cases in our series had frequent but generally non-recurring abnormalities; the only abnormality seen in more than one case was a translocation involving chromosome 2p13. Other published series using the EGIL definition of BAL also show a relatively high frequency of t(9;22) and 11q23 translocations. 10, 12, 16, 18 Although these latter series also may have included cases of what we would call aBLL, these results at least suggest that there may be a continuum between aBLL and BAL. There is at least one report that specifically describes an association between t(9;22) and a bilineal leukemia with a predominantly B-lymphoid and minor myeloid component. 19 Other reports of cytogenetic abnormalities in biphenotypic leukemia have included, among other lesions, recurrent abnormalities of 6q 11, 19 or 5q deletions, 15, 17, 19 neither of which was present in our series. There has also been a report of one case with a T-My leukemia having a translocation involving chromosome 2p13, 10 though with a different partner than in our case. Even if there is overlap between aBLL and the more frequent BAL cases that have dual lineage antigen expression on the same cells, there also appear to be cases in which aBLL and BAL are different. This is especially so in cases of leukemias associated with MLL rearrangements. Even when these tumors appear predominantly lymphoid, they may express CD13, CD33, CD15 and CD65s in variable frequency, 11 and some may thus be classified as BAL according to EGIL. However, in other cases, as embodied by our cases 14 and 17, cases with MLL rearrangements can show distinct B-lineage and monoblastic components and meet criteria for aBLL, 13 though it would seem that such cases are different from other biphenotypic cases.
The outcome of patients with aBLL in our series was poor. Only 6/16 patients (38%) entered remission, and all but two have relapsed or died. Therapy included either ablative chemotherapy most often directed at the myeloid component or stem cell transplantation. Patients with B-My or T-My leukemia appeared to fare equally badly. It was not possible to predict outcome based on the relative proportions of myeloid or lymphoid blasts, indicating that even small components of a second lineage are likely to be significant.
Most other series of BAL have also shown poor outcome. 12, [14] [15] [16] [17] In one series, it was suggested that the poor outcome in BAL was largely due to adverse cytogenetics, particularly the presence of the BCR-ABL translocation. 12 In our series, one of the only two long-term survivors (case no. 12) had a karyotype that included a t(9;22).
Cases of biphenotypic leukemia have been reported to relapse as either acute myeloid or acute lymphoid leukemia. 8, 20 In several of the cases in our series, we saw changes in proportions of blasts of different lineages following therapy, with cases 4, 12 and 13 clearing only the myeloid component, while case 9 cleared only the T-cell component. Cases 2 and 4 relapsed as T-ALL. Some cases of so-called lineage switch 21 may in fact represent bilineage cases where a minor component was not detected at diagnosis. One of the cases in our series was initially diagnosed elsewhere as T-ALL, but was proved on our analysis to be aBLL; we did not have access to the original sample to determine if there might have been a minor myeloid component. However, other samples after therapy in this case showed only myeloid blasts and might have been interpreted as lineage switch had aBLL not been detected.
The mechanism by which aBLL arises is uncertain. It seems most likely that it arises as a clonal proliferation of a primitive cell with ability to differentiate in both myeloid and lymphoid directions; there is no proof that the two lineages represent distinct clones. The fact that T-My and B-My leukemias are seen in about equal frequency, while T-B leukemias rarely if ever occur may have implications for models of normal hematopoiesis. 22 In summary, aBLL is rare leukemia, constituting about 1-2% of cases of acute leukemia that contains B-or T-lymphoid along with myeloid blasts. Outcome is poor. It includes cases that might be defined as BAL, but also includes cases that might not satisfy criteria for BAL because of an insufficient proportion of blasts of one lineage. Although a dual population of blasts may be morphologically apparent, light scatter properties and immunophenotypic profiles are essential for recognition of aBLL. In common with other descriptions of BAL, cytogenetic analysis indicates that many B-myeloid cases are characterized by t(9;22) or 11q23 abnormalities, while T-myeloid cases exhibit frequent but generally non-recurring abnormalities.
